Table 1.

Characteristics of the studied patient samples

Patient number	Rai stage	del 17p (FISH)	FR	FAR	Other cytogenetics (FISH)	Previous treatment	CDC	% B cell lysis after treatment with 5 μg/ml either anti-CCR7 or alemtuzumab	% B cell lysis after treatment with 0.5 μg/ml either anti-CCR7 or alemtuzumab
1	I	y	n		del 13q	t (1)	y	97.80 vs 92.45	93.64 vs 83.16
2	0	y	n			ut	y	94.27 vs 89.70	94.45 vs 81.64
3	III	n	n			t (1)	n	nd	nd
4	IV	n	y			t (2)	y	98.66 vs 92.24	93.35 vs 83.26
5	IV	n	y			t (5)	y	97.96 vs 96.62	72.36 vs 77.40
6	O	y	n			ut	y	96.94 vs 76.10	97.08 vs 17.16
7	I	y	n			t (1)	y	96.84 vs 16.69	91.27 vs 0
8	III	n	n			t (1)	n	nd	nd
9	IV	y	n			t (1)	y	87.82 vs 74.95	87.94 vs 5.18
10	IV	y	y	y	de l 11q	t (5)	y	99.06 vs 66.42	99.06 vs 12.83
11	IV	y	y			t (4)	y	97.50 vs 92.76	90.84 vs 69.04
12	IV	n	y		del 11q	t (2)	y	91.06 vs 39.24	82.13 vs 30.62
13	IV	y	y		del 11q, del 13q	t (4)	y	83.31 vs 53.87	63.18 vs 27.73
14	IV	y	y	y	del 11q	t (3)	y	94.55 vs 48.94	94.54 vs 33.37
15	0	n	n			t (1)	n	nd	nd
16	IV	n	y		del 11q	t (2)	y	99.14 vs 96.98	86.72 vs 74.01
17	I	y	n		del 13q	t (1)	y	98.97 vs 83.29	98.52 vs 39.12
18	I	n	n			ut	n	nd	nd
19	IV	y	y			t (4)	y	82.04 vs 63.29	80.02 vs 18.45
20	0	n	n			ut	n	nd	nd
21	I	n	n			ut	n	nd	nd
22	0	n	n			ut	n	nd	nd
23	0	na	n			ut	n	nd	nd

The table presents the cytogenetic abnormalities and refractory status of the studied patients, the CDC activity of anti-CCR7 mAb and alemtuzumab (anti-CD52)

FR fludarabine-refractory CLL, FAR CCL refractory to fludarabine and alemtuzumab, FISH fluorescence in situ hybridization, CDC complement-dependent cytotoxicity, y yes, n no, na not available, nd not determined, ut untreated, t treated (number of lines)